EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting EBV gp42 for nasopharyngeal carcinoma prevention

Cong Sun, Le-Le Zhang, Mu-Sheng Zeng

Molecular Therapy · 2025-07 · 33 (7) · 2987-2989

DOI: 10.1016/j.ymthe.2025.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-07. Verfasst von Cong Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Noncommunicable Chronic Disease-National Science and Technology Major Project, National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-associated malignancy, remains a significant public health burden in endemic regions such as southern China.1 While early detection through serologic biomarkers has improved outcomes, the development of preventive strategies remains a challenge. Recent work by Kong et al. highlights the protective role of high gp42-immunoglobulin (Ig)G titers against NPC risk, offering new insights into EBV immunobiology and opportunities for vaccine design.

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center…

Förderung

  • Noncommunicable Chronic Disease-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China Stem Cell and Translational Research
  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Sun, C., Zhang, L. L., & Zeng, M. S. (2025). Targeting EBV gp42 for nasopharyngeal carcinoma prevention. Molecular Therapy, 33(7), 2987-2989. https://doi.org/10.1016/j.ymthe.2025.06.005

Vancouver

Sun C, Zhang LL, Zeng MS. Targeting EBV gp42 for nasopharyngeal carcinoma prevention. Molecular Therapy. 2025;33(7):2987-2989. doi:10.1016/j.ymthe.2025.06.005

BibTeX
@article{Sun2025,
  author = {Sun, Cong and Zhang, Le-Le and Zeng, Mu-Sheng},
  title = {Targeting EBV gp42 for nasopharyngeal carcinoma prevention},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {7},
  pages = {2987--2989},
  doi = {10.1016/j.ymthe.2025.06.005}
}
Kostenlos starten →